India Glycols has confirmed that its demerger scheme into three distinct entities is now effective as of September 1, 2026. The company filed the certified true copy of the National Company Law Tribunal (NCLT) order with the Registrar of Companies on this date, finalizing the separation of its business verticals.

Demerger structure and effective date

The corporate restructuring results in three separate companies emerging from the current India Glycols entity. The NCLT, Allahabad Bench, sanctioned the Scheme of Arrangement among India Glycols Limited (the Demerged Company), Ennature Bio Pharma Limited (Resulting Company 1), and IGL Spirits Limited (Resulting Company 2).

The effective date of the scheme is September 1, 2026. Consequently, the resulting companies have ceased to be subsidiaries of India Glycols Limited.

Shareholding pattern and listing

Shareholders holding India Glycols shares on the record date of September 2, 2026, will receive shares in the new entities based on a specific ratio. For every one equity share held in India Glycols Limited, shareholders are entitled to:

• One equity share of IGL Spirits Limited.
• One equity share of Ennature Bio Pharma Limited for every three equity shares held in India Glycols Limited.

For example, a shareholder with 300 India Glycols shares will receive 300 IGL Spirits shares and 100 Ennature Bio Pharma shares, totaling 700 shares across the three entities. India Glycols Limited remains listed on both BSE and NSE. The management of IGL Spirits Limited and Ennature Bio Pharma Limited will apply for listing of their shares on the respective bourses.

Strategic benefits

The demerger aims to create three separate companies with clear business focus. This structure enables improved management oversight and efficient allocation of resources towards growth. Each entity can now manage its capital, investments, and resources based on specific business requirements, facilitating more efficient capital utilization.

India Glycols has outlined plans to launch one new active pharmaceutical ingredient (API) each year, expand into the dietary fibre segment, and grow its market share in nicotine and thiocolchicoside.

Strategic growth areas

The company's plans span multiple product categories, reflecting a broad-based approach to business development. The key strategic initiatives include:

• Launch of one new API annually
• Expansion into the dietary fibre segment
• Increased market share in nicotine
• Increased market share in thiocolchicoside

Product focus overview

The following table summarises India Glycols' announced strategic priorities:

These initiatives indicate India Glycols' intent to diversify its product portfolio across pharmaceutical ingredients and specialty nutrition, while deepening its presence in established therapeutic and nutraceutical categories.